According to IMARC Group latest report titled “T-cell Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a comprehensive analysis of the industry, which comprises insights on T-cell therapy market report. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The global T-cell therapy market is expected to exhibit a CAGR of 16.9% during 2022-2027.
T-cell therapy is a type of immunotherapy wherein doctors collect immune cells, modify them in a laboratory, and provide them the power to recognize and kill cancer cells efficiently. It is a remarkably promising treatment for cancer patients. T-cells are the backbone of CAR-T cell therapy, which are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens.
Market Trends:
The global market is majorly driven by strategic investments by public and private agencies to develop effective cancer treatments. Apart from this, numerous operating entities are collaborating with research communities across the globe, thus resulting in a shift in focus on accelerating the development of CAR-T therapies to expand the therapeutic application landscape. Moreover, the presence of strong research, a commercial base, and a high number of clinical trials being conducted for T-cell therapies are catalyzing the market. Besides this, a considerable rise in the substantial number of medical centers offering T-cell therapy across the globe is strengthening the market. Additionally, the growing number of people diagnosed with bone marrow and blood-forming tissue illnesses is also providing a boost to the demand for T cell therapy.
Explore Full Report with Table of Contents: https://www.imarcgroup.com/t-cell-therapy-market
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
- Amgen Inc.
- Aurora Biopharma Inc.
- bluebird bio Inc
- Bristol-Myers Squibb Company
- Fate Therapeutics
- Gilead Sciences Inc.
- Merck KGaA
- Mustang Bio Inc.
- Novartis AG
- Pfizer Inc.
- Sorrento Therapeutics Inc.
- TCR2 Therapeutics
T-cell Therapy Market Segmentation:
Our report has categorized the market based on region, modality, therapy type and indication.
Breakup by Modality:
- Research
Breakup by Therapy Type:
- CAR T-cell based
- T Cell Receptor (TCR) based
- Tumor Infiltrating Lymphocytes (TIL) based
Breakup by Indication:
- Hematologic Malignancies
- Lymphoma
- Leukemia
- Myeloma
- Solid Tumors
- Melanoma
- Brain and Central Nervous System
- Liver Cancer
- Others
- Others
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022-2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe:- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800